This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Lee Waise Lee as Edward Lai (黎永廉), Secretary of Justice / co-conspirator of Peter Choi King Kong Lam as Gary Fu, Ex-Senior Inspector of Police Vincent Lam as Neo Chan, Ex-Senior Inspector of Police Wong Man-piu as Eric Ma, Ex-Senior Inspector of Police Brian Wong as Mark Cheng, Ex-Senior Inspector of Police Felix Lok as C.Y. Ma, Member of the Legislative Council / Chairman of Security Panel Council / co-conspirator of Peter Choi Terence Yin as To Man, Chief Superintendent, Director of Information Technology Jeannie Chan as Nicole Chan, ICAC Assistant Investigator Kathy Yuen as Cecilia Lai, Probationary Inspector of Police and secretary to Commissioner Dexter Young as Senior Inspector of Police, Technology Crime Division Queenie Chu as Amber Tsui, cigar lounge owner / co-conspirator of Peter Choi Leila Tong as Karen Tang, hostage
== History == Evidence that the small intestine controls the release of bile was uncovered as early as 1856, when French physiologist Claude Bernard showed that when dilute acetic acid was applied to the orifice of the bile duct, the duct released bile into the duodenum. In 1903, the French physiologist Émile Wertheimer showed that this reflex was not mediated by the nervous system. In 1904, the French physiologist Charles Fleig showed that the discharge of bile was mediated by a substance that was conveyed by the blood. There remained the possibility that the increased flow of bile in response to the presence of acid in the duodenum might be due to secretin, which had been discovered in 1902. The problem was finally resolved in 1928 by Andrew Conway Ivy and his colleague Eric Oldberg of the Northwestern University Medical School, who found a new hormone that caused contraction of the gall bladder and that they called "cholecystokinin". In 1943, Alan A. Harper and Henry S. Raper of the University of Manchester discovered a hormone that stimulated pancreatic enzyme secretion and that they named "pancreozymin"; however, pancreozymin was subsequently found to be cholecystokinin. Swedish biochemists Johannes Erik Jorpes and Viktor Mutt undertook the monumental task of isolating and purifying porcine cholecystokinin and then determining its amino acid sequence. They finally presented porcine cholecystokinin's amino acid sequence in 1968.
== History == Yohimbe (Pausinystalia johimbe) is a tree that grows in western and central Africa; yohimbine was named as originally extracted from the bark of yohimbe in 1896 by Adolph Spiegel (but see § Aspidosperma quebracho-blanco below). Yohimbe is used in folk medicine as an aphrodisiac. In 1900, it attracted scientific interest in Germany, where an initial report claimed that yohimbe exerted a strong aphrodisiacal effect in animals and humans. Attention soon shifted from the plant to its active constituents, particularly yohimbine. In 1943 the correct constitution of yohimbine was proposed by Witkop. Fifteen years later, a team led by Eugene van Tamelen used a 23-step synthesis to become the first persons to achieve the synthesis of yohimbine.
=== Bibliography === I Can't Make This Up: Life Lessons (2017) The Decision: Overcoming Today's BS for Tomorrow's Success (2020) Marcus Makes a Movie (2021) Marcus Makes It Big (2022) Monsters and How to Tame Them: Taking Charge of the Voices in Your Head (2022)
=== Carbonate compensation depth === The carbonate compensation depth (CCD) is the point in the ocean where the rate of precipitation of calcium carbonate is balanced by the rate of dissolution due to the conditions present. Deep in the ocean, the temperature drops and pressure increases. Increasing pressure also increases the solubility of calcium carbonate. Calcium carbonate is unusual in that its solubility increases with decreasing temperature. The carbonate compensation depth ranges from 4,000 to 6,000 meters below sea level in modern oceans, and the various polymorphs (calcite, aragonite) have different compensation depths based on their stability.
Sources: en.wikipedia.org
The emu (; Dromaius novaehollandiae) is a species of flightless bird endemic to Australia, where it is the tallest native bird. It is the only extant member of the genus Dromaius and the third-tallest living bird after its African ratite relatives, the common ostrich and Somali ostrich. The emu's native ranges cover most of the Australian mainland. The Tasmanian, Kangaroo Island and King Island subspecies became extinct after the European settlement of Australia in 1788. The emu has soft, brown feathers, a long neck, and long legs. It can grow up to 1.9 m (6 ft 3 in) in height. It is a robust bipedal runner that can travel great distances, and when necessary can sprint at 48 km/h (30 mph). It is omnivorous and forages on a variety of plants and insects, and can go for weeks without eating. It drinks infrequently, but takes in copious amounts of fresh water when the opportunity arises. Breeding takes place in May and June, and fighting among females for a mate is common. Females can mate several times and lay several clutches of eggs in one season. The male incubates the eggs; during this process he hardly eats or drinks and loses a significant amount of weight. The eggs hatch after around eight weeks, and the young are nurtured by their fathers. They reach full size after around six months, but can remain as a family unit until the next breeding season. The emu is sufficiently common to be rated as a least-concern species by the International Union for Conservation of Nature.
=== Interoperability === The DASH7 Alliance is currently working on a certification program that functionally tests the DASH7 devices. The certification is composed of a set of test scenarios covering transactions in different stack configurations (channel, QoS, security). The physical wireless interface is not covered by the certification and will have to comply to local radio regulations.
The 'top-down' communication strategy is susceptible to interception, more so further down the hierarchy being communicated to; Maintaining written records jeopardizes the security of the organization and relies on increased security measures; Infiltration at lower levels in the hierarchy can jeopardize the entire organization (a 'house of cards' effect); and, Death, injury, incarceration or internal power struggles dramatically heighten the insecurity of operations. While bureaucratic operations emphasize business processes and strong hierarchies, these are based on enforcing power relationships rather than an overlying aim of protectionism, sustainability or growth.
=== Risk factors === As PNP is ultimately caused by the presence of a tumor, it is not contagious. There is no known way to predict who will become afflicted with it. Patients with cancer are therefore a group at risk. Although PNP has been known to affect all age groups, it is more likely to afflict middle-aged to older patients.
The two substrates of this enzyme are estradiol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are estrone, reduced NADH, and a proton. The enzyme can alternatively use nicotinamide adenine dinucleotide phosphate as its cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is estradiol-17beta:NAD(P)+ 17-oxidoreductase. Other names in common use include 20alpha-hydroxysteroid dehydrogenase, 17beta,20alpha-hydroxysteroid dehydrogenase, 17beta-estradiol dehydrogenase, estradiol dehydrogenase, estrogen 17-oxidoreductase, and 17beta-HSD. This enzyme participates in androgen and estrogen metabolism.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.